对高度可变药物的缩放平均生物等效方法:平衡平衡软限值和EMA的2010年指南 (改善其I型错误控制的一些方法)
Joel Muñoz1, Jordi Ocaña2, Rolando Suárez1,3
1Department of Statistics, University of Concepcion, Concepcion, Chile.
Statistics in medicine
|February 5, 2024
概括
对于高度可变的药物,参考尺度平均生物等效 (RSABE) 方法存在I型错误问题. 改进的"平衡" (LO) 方法减少了这些错误,复制的设计显示出更好的稳定性对抗异性.
科学领域:
- 药理动力学和药物开发
- 生物统计学 生物统计学
- 监管科学 监管科学
背景情况:
- 欧洲药物管理局 (EMA) 的参考量级平均生物等价性 (RSABE) 方法在控制高度可变药物的I型错误方面面临挑战,特别是接近30%的变化系数 (CV).
- 这一关键值标志着生物等价性 (BE) 极限从恒定变为线性缩放的转变,影响了监管决策.
研究的目的:
- 分析和比较基于"平衡" (LO) 软西格扩展极限的生物等效 (BE) 推断方法与EMA的RSABE方法.
- 用复制和部分复制的交叉设计来评估这些方法.
- 调查异种粘度对I型错误率的影响,并评估设计稳定性.
主要方法:
- 欧洲药物管理局的RSABE方法与最初提出的"平衡" (LO) 方法进行生物等效推断的比较.
- 介绍和评估两个改进的LO方法:一个使用Howe的方法,另一个纠正估计错误.
- 在各种条件下分析I型错误率,包括不同的变化系数 (CV) 和异性.
- 对复制和部分复制交叉车设计的性能评估.
主要成果:
- 最初的LO方法与RSABE相比显示了减弱的I型错误通货膨胀,但仍然存在问题.
- 对LO方法的两个提议的改进进一步减少了I型错误的通货膨胀,尽管它并没有完全消除.
- 异种粘性显著影响I型错误率,导致通货膨胀或通货紧缩,具体取决于变化差异的设计和方向.
- 与部分复制的设计相比,复制的交叉车设计显示出更高的稳定性和更好的维护,在异种性下进行了改进.
结论:
- 虽然"平衡" (LO) 方法得到了改进,但需要进一步改进,以便在高度可变的药物的生物等价性研究中完全控制I型错误.
- 复制的交叉设计为生物等价性评估提供了更强大的框架,特别是在处理潜在的异种性时.
- 该研究强调了在评估生物等价性时考虑设计选择和可变性特征的重要性,特别是在具有高可变性的药物中.
相关概念视频
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
128
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
128
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
507
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
507
Regression Toward the Mean
6.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K


